



(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 31/4178 (2006.01)

A61K 31/4422 (2006.01) A61K 31/404 (2006.01)

(21) International Application Number:

PCT/KR2017/012396

(22) International Filing Date:

03 November 2017 (03.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2016-0145518 03 November 2016 (03.11.2016) KR

(71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18358 (KR).


(72) Inventors: CHO, Hyuk Jun; B-301, 46, Deogyong-daero 381beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 16358 (KR). LIM, Sol Ee; #905, 17-9, Gwongwang-ro 196beon-

gil, Paldal-gu, Suwon-si, Gyeonggi-do 16488 (KR). IM, Ho Taek; 117-1204, 27, Yonggu-daero 2394beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16909 (KR). KIM, Yong Il; 732-504, 52, Jeongja-ro 42beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 16325 (KR). PARK, Jae Hyun; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16707 (KR). WOO, Jong Soo; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 16420 (KR).

(74) Agent: KIM, Sung Ho et al.; (WANNABE Patent & Law Firm), (Hongeun Bldg., Yeoksam-dong) 5F, 8, Teheran-ro 8-gil, Gangnam-gu, Seoul 06233 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,

(54) Title: PHARMACEUTICAL COMPLEX FORMULATION COMPRISING AMLODIPINE, LOSARTAN AND CHLORTHALIDONE



(57) Abstract: The present invention relates to a pharmaceutical complex formulation including amlodipine, losartan, and chlorthalidone as active ingredients. The pharmaceutical complex formulation of the present invention including amlodipine, losartan and chlorthalidone as the active ingredients exhibits excellent dissolution characteristics of the active ingredients, and has high content uniformity and heat stability. Therefore, the complex formulation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has excellent quality and heat stability.

[Continued on next page]



PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

26 July 2018 (26.07.2018)